EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Bile Acid Malabsorption in Chronic Diarrhea: Pathophysiology and Treatment

Alan N Barkun, Jonathan Love, Michael Gould, Henryk Pluta, Hillary Steinhart

Canadian Journal of Gastroenterology · 2013 · 27 (11) · 653-659

DOI: 10.1155/2013/485631 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Canadian Journal of Gastroenterology, 2013. Verfasst von Alan N Barkun und 4 weiteren Autor:innen. Die Arbeit wurde bisher 89-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bile acid malabsorption (BAM) is a common but frequently under-recognized cause of chronic diarrhea, with an estimated prevalence of 4% to 5%. METHODS: The published literature for the period 1965 to 2012 was examined for articles regarding the pathophysiology and treatment of BAM to provide an overview of the management of BAM in gastroenterology practice. RESULTS: BAM is classified as type 1 (secondary to ileal dysfunction), type 2 (idiopathic) or type 3 (secondary to gastrointestinal disorders not associated with ileal dysfunction). The estimated prevalence of BAM is >90% in patients with resected Crohn disease (CD) and 11% to 52% of unresected CD patients (type 1); 33% in diarrhea-predominant irritable bowel syndrome (type 2); and is a frequent finding postcholecystectomy or postvagotomy (type 3). Investigations include BAM fecal bile acid assay, 23-seleno-25-homo-tauro-cholic acid (SeHCAT) testing and high-performance liquid chromatography of serum 7-α-OH-4-cholesten-3-one (C4), to determine the level of bile acid synthesis. A less time-consuming and expensive alternative in practice is an empirical trial of the bile acid sequestering agent cholestyramine. An estimated 70% to 96% of chronic diarrhea patients with BAM respond to short-course cholestyramine. Adverse effects include constipation, nausea, borborygmi, flatulence, bloating and abdominal pain. Other bile acid sequestering agents, such as colestipol and colesevelam, are currently being investigated for the treatment of BAM-associated diarrhea. CONCLUSIONS: BAM is a common cause of chronic diarrhea presenting in gastroenterology practice. In accordance with current guidelines, an empirical trial of a bile acid sequestering agent is warranted as part of the clinical workup to rule out BAM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AllylamineAnimalsAnion Exchange ResinsBile Acids and SaltsCholestyramine ResinChronic DiseaseColesevelam HydrochlorideColestipolDiarrheaHumansMalabsorption SyndromesPractice Guidelines as TopicPrevalence

Substanzen

Anion Exchange ResinsBile Acids and SaltsCholestyramine ResinAllylamineColestipolColesevelam Hydrochloride

Zitieren

APA

Barkun, A. N., Love, J., Gould, M., Pluta, H., & Steinhart, H. (2013). Bile Acid Malabsorption in Chronic Diarrhea: Pathophysiology and Treatment. Canadian Journal of Gastroenterology, 27(11), 653-659. https://doi.org/10.1155/2013/485631

Vancouver

Barkun AN, Love J, Gould M, Pluta H, Steinhart H. Bile Acid Malabsorption in Chronic Diarrhea: Pathophysiology and Treatment. Canadian Journal of Gastroenterology. 2013;27(11):653-659. doi:10.1155/2013/485631

BibTeX
@article{Barkun2013,
  author = {Barkun, Alan N and Love, Jonathan and Gould, Michael and Pluta, Henryk and Steinhart, Hillary},
  title = {Bile Acid Malabsorption in Chronic Diarrhea: Pathophysiology and Treatment},
  journal = {Canadian Journal of Gastroenterology},
  year = {2013},
  volume = {27},
  number = {11},
  pages = {653--659},
  doi = {10.1155/2013/485631}
}
Kostenlos starten →